Krsek initially provided a loan to Carebot, which has now been converted into equity—though the exact monetary value of his investment was not disclosed. Carebot’s valuation, according to its founders, is estimated to be in the hundreds of millions of Czech koruna.
Jan Černý, head of BHM Group, commented: “We are very satisfied with our investment in Carebot and see great potential in the company. It has an excellent team and a customer-oriented product in a market where AI implementation brings tremendous benefits to both patients and doctors.” BHM Group plans to continue supporting the startup, either financially or through its own medical technologies division.
Carebot is an innovative Czech med-tech startup that develops artificial intelligence (AI) solutions to assist in interpreting medical imaging—starting with chest X-rays. The aim is to equip healthcare professionals with tools that enhance diagnostic accuracy and workflow efficiency, particularly in cases where subtle abnormalities might be missed by human observers.
It was founded in 2021 by Daniel Kvak, Karolína Kvaková, and Matěj Misař. Its AI system for evaluating chest X-ray images is already utilized by physicians across over one hundred hospitals in seven European countries—namely the Czech Republic, Slovakia, Poland, Hungary, Germany, Bulgaria, and Greece. The system processes more than one million images annually and reportedly achieves up to 95% accuracy.
Carebot entered the market in March 2024, following certification, and has since been generating revenues in the hundreds of thousands of euros, although the startup is still operating at a loss. The founders retain the majority stake in the company.
